HIGHLIGHTS
- who: Meijie Tian and colleagues from the National Cancer Institute UK University of have published the paper: An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma, in the Journal: (JOURNAL)
- what: The authors aimed to identify optimal CARs against glypican 2 (GPC2) or CD276 (B7-H3) which were highly but heterogeneously expressed in neuroblastoma (NB) a lethal extracranial solid tumor of childhood. The authors showed the expression of both targets to be high but heterogenous among NB tumors, predicting that some of the patients with low expression of GPC2 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.